Niacin.

The body makes part of its own NAD from tryptophan through the kynurenine pathway, so dietary tryptophan and niacin feed the same pool. Dietary equivalents count roughly 60 mg of tryptophan as 1 mg of niacin.

Kynureninase, the step that lets tryptophan continue toward NAD, is a PLP enzyme and depends on vitamin B6. When B6 is short the pathway diverts and less NAD is generated from tryptophan, so more of the demand falls on niacin itself.

Kynurenine monooxygenase, another step on the route from tryptophan to NAD, uses riboflavin-derived FAD. Riboflavin status therefore influences how much NAD the body can build without preformed niacin.

The first committed step of the tryptophan to NAD route is run by heme enzymes that hold iron at the active site. Iron availability shapes how readily tryptophan enters the pathway that supplements the niacin supply.

Nicotinic acid is converted through the Preiss-Handler route to nicotinic acid mononucleotide, then to NAD. Nearly every named use of niacin runs through this conversion.

Both forms converge on NAD, but nicotinic acid activates the HCAR2 receptor on skin and fat cells while the amide does not, which is why only the acid form causes the flush. Formulators pick between them, or blend, on that basis.

NMN enters the NAD pool through the salvage route while nicotinic acid enters through Preiss-Handler. The two routes are separate for most of their length and meet only at NAD.

NR is phosphorylated to NMN then adenylylated to NAD, bypassing the enzymes nicotinic acid uses. Combining them covers both entry points into the same pool.

Nicotinamide generated downstream of niacin is cleared by methylation using S-adenosylmethionine, and TMG restores that donor by remethylating homocysteine. Higher B3 intake raises the methyl draw.

Methylfolate feeds homocysteine remethylation and so helps regenerate the S-adenosylmethionine spent on nicotinamide methylation. This is the folate arm of the same support TMG provides.

The niacin flush is driven by prostaglandin D2 released from skin cells, and salicylates from willow bark blunt that release by inhibiting cyclooxygenase. This is the established reason a salicylate is taken ahead of nicotinic acid.

The body makes a share of its own niacin from tryptophan, and one of the committed steps in that route runs on pyridoxal 5-phosphate. When B6 coenzyme status is low, more tryptophan leaves through side branches and less arrives as nicotinic acid. Pairing the active B6 form with niacin covers both the dietary source and the endogenous route. This is settled biochemistry rather than a combination trial result.

Nicotinic acid reaches NAD through the Preiss-Handler route, and the final step swaps an acid group for an amide using nitrogen donated by glutamine. Glutamine is abundant in most diets, so this is a dependency rather than a shortfall people usually run into. It is worth stating because it explains why NAD synthesis is not a single-nutrient process. No human combination trial is being described here.

Every phosphotransfer in the NAD assembly line uses ATP complexed with magnesium, including the adenylylation step that joins nicotinic acid mononucleotide to AMP. Magnesium is the counter-ion that makes those transfers possible. The pairing is mechanistic support for the pathway, not a claim that adding magnesium raises NAD.

Reduced glutathione is restored from its oxidised form by glutathione reductase, and the electrons come from NADPH. NADPH is phosphorylated NAD, so niacin status sits upstream of the whole recycling loop. The relationship is directional: the dinucleotide pool supports glutathione turnover rather than the other way around.

N-acetylcysteine feeds the cysteine that glutathione is built from, while niacin-derived NADPH is what keeps recycling the glutathione already made. Two different limits on the same system, which is why they are often formulated together. The rationale is mechanistic; head-to-head human data on the pair is not what is being cited.

Complex I oxidises NADH and passes the electrons to ubiquinone, so the niacin-derived carrier and the quinone carrier are consecutive links in the same chain. A shortfall at either point slows the same flux. This describes normal energy metabolism and does not imply a measured combination effect.

Nicotinamide that is not used is cleared by methylation to N1-methylnicotinamide, and each methyl group comes from S-adenosylmethionine. Larger intakes therefore draw on the methyl pool that choline and betaine also feed. Formulators often pair methyl donors with higher-dose niacin for this reason. The interaction is directional and dose-dependent rather than a fixed ratio.

S-adenosylmethionine is the methyl donor spent when surplus nicotinamide is methylated for excretion, and the product N1-methylnicotinamide appears in the co-study record alongside niacin. The relationship is a draw on a shared pool, so it matters most at higher intakes. It is a metabolic accounting point, not a measured clinical outcome.

Methionine is converted to S-adenosylmethionine, which supplies the methyl group for nicotinamide clearance. Intake of the vitamin and intake of methyl donors therefore sit on the same ledger. Stating this is what keeps a high-dose formulation honest about what else it is drawing on.

Thiamine pyrophosphate runs the pyruvate and alpha-ketoglutarate decarboxylation steps, and each of those steps hands electrons to NAD. Neither coenzyme can carry the flux without the other. B-complex formulation reflects this rather than any single-nutrient finding.

Pantothenic acid becomes coenzyme A, which accepts the acetyl group at the same reaction where NAD accepts the electrons. The two vitamins are joint inputs to one enzyme complex. This is textbook cofactor pairing and needs no trial to state.

Lipoic acid is reduced during the decarboxylation cycle and then reoxidised by an enzyme that hands the electrons to NAD. Supplemental lipoate also participates in broader redox cycling that draws on the same dinucleotide pool. The mechanistic tie is clear; how much a supplemental pairing changes anything measurable in people has not been shown here.

One commercial niacin form is literally inositol esterified with six nicotinate groups, which slows the release of free nicotinic acid and blunts the flush. The inositol is the carrier, not an added active. Release from the ester in people is incomplete and variable, which is the trade-off that comes with it.

Chromium and niacin appear together in the co-study record and were given as a combined supplement to transition dairy cows, with metabolic and production measures reported. That is livestock production data, not human evidence, and the outcomes measured were animal performance markers. The pairing is a research question rather than an established human combination.

Nicotinic acid at gram-level intakes reduces free fatty acid release from fat cells, while long-chain omega-3s act mainly on hepatic triglyceride assembly. Because the routes differ, the two are often formulated alongside each other in lipid-support products. This is a structure-function statement about normal lipid handling and belongs with a clinician when intakes get large.

Berberine acts largely through hepatic LDL receptor expression and AMPK signalling, which does not overlap with the adipocyte receptor route that nicotinic acid uses. Stacking them is common in lipid-support formulas. Neither the size nor the direction of a combined effect is settled, so read the pairing as mechanistic.

Red yeast rice supplies monacolin K, an HMG-CoA reductase inhibitor, and gram-level nicotinic acid has long been combined with that drug class in lipid research. Combined use raises the practical questions of muscle symptoms and liver enzyme monitoring that apply to the drug class itself. This pairing is a clinician-supervised decision, not a self-directed stack.

Nicotinic acid becomes a mononucleotide only when it is joined to phosphoribosyl pyrophosphate, a phosphorylated sugar. Phosphate also appears alongside niacin in the co-study record. Dietary phosphorus is rarely the limiting factor, so this is background pathway detail rather than a reason to co-supplement.